A ndrogen signaling, particularly the androgen receptor (AR) activity plays a crucial role in prostate cancer (PCa) development. The primary role of AR in PCa is believed to regulate expression of the genes that are essential for prostate tumorigenesis. As a transcriptional factor, after binding to androgen, AR binds to specific DNA sequences and consequently recruits RNA polymerase II and a basal transcriptional complex for efficient transcription of AR target genes. Deregulation of the AR target genes such as PSA, SLC45A3, FASN, and TMPRSS2 has been shown to promote PCa cell growth and tumorigenesis (reviewed in ref. 1) .
AR-mediated transcriptional regulation is dependent on AR activity, which is often deregulated through mechanisms such as mutations in the AR gene, increased expression of AR protein, growth factor-induced activation of AR, or aberrant function of AR-interacting proteins, particularly the coactivators. AR coactivators enhance AR activity and PCa cell survival through phosphorylation, sumoylation, and stabilization of AR (reviewed in ref. 2) . Recently, AR acetylation was found to play a key role in AR-mediated transactivation and prostate tumorigenesis (3) . Acetylases that are AR coactivators include p300, a histone acetylase, the p300-CBP-associated factor (P/CAF), and the Tat interactive protein 60 (TIP60). They acetylate AR at three individual residues, lysine 630, 632, and 633 in a conserved lysine motif of AR ( 630 KLKK 633 ) (3) (4) (5) . Following AR acetylation, these proteins facilitate AR transcriptional activity by remodeling chromatin via histone acetylation and by recruiting RNA polymerase II complex to the AR-regulated promoters (3, 6) . Like other AR coactivators, acetylases such as p300 are up-regulated in PCa (7) . Up-regulation of p300 enhances AR acetylation, which is critical for AR activity to regulate AR target genes leading to PCa progression (3) . Thus, aberrant activation of AR in PCa has been attributed, at least in part, to up-regulation of AR coactivators such as acetylases. Emerging evidence indicates that inhibition of AR coactivators is an effective antiandrogen therapy (8) . Recently, it has become evident that inactivation of p300 inhibits prostate tumorigenesis (9) . Therefore, identifying new AR coactivators and elucidating their roles in androgen signaling through AR may provide a critical drug target for therapeutic intervention in PCa.
In a genetic analysis of DNA damage response genes in PCa, we previously found that ARD1 was not mutated but rather upregulated in PCa (10) . ARD1 induces acetylation in a large group of proteins that contain the N-α-or ε-acetylation sites (11) . By acetylating specific substrate proteins, ARD1 plays important roles in apoptosis, hypoxia, autophagy, and cell proliferation (12) (13) (14) (15) . Significantly, recent reports indicate that dysregulation of ARD1 is associated with tumorigenesis in a variety of human cancers including colorectal (16) , breast (14) , and lung (15, 17) . However, the role of ARD1 in PCa remains unknown.
In this study, we identified ARD1 as a unique androgen-induced AR regulator in PCa. By overexpressing or silencing ARD1, we demonstrated that ARD1 is crucial for AR-mediated gene transcription, PCa cell proliferation, and xenograft tumor growth. Importantly, we revealed an important role of ARD1 in prostate tumorigenesis through its interaction with and acetylation of AR. Our findings suggest that dysregulation of ARD1 may contribute to AR-mediated gene transcription and PCa development and that ARD1 is a potential therapeutic target for PCa.
Results
ARD1 Is Up-Regulated in PCa Cell Lines and Tumor Tissues. To determine the role of ARD1 in prostate tumorigenesis, we first measured ARD1 protein levels in 12 prostatic epithelial cell lines by Western blotting. Levels of ARD1 were higher in all 9 PCa cell lines than in 3 normal prostatic epithelial cell lines (Fig. 1A,  Left) . Moreover, ARD1 levels were the highest in cell lines with intact AR (LNCaP, C4-2B, and MDA-PCa 2b) (Fig. 1A, Left) . The average level of ARD1 was more than doubled in PCa cell lines with intact AR compared with those without and was approximately fivefold higher than that in the normal prostate cell lines (Fig. 1A, Right) . The high levels of ARD1 were also observed by Western blotting in 11 of 12 freshly frozen prostate tumor tissues compared with their matched adjacent normal prostate tissues (Fig. 1B, Left) . The levels of ARD1 in the majority of PCa tissues were more than doubled those in the matched normal tissues (Fig. 1B, Right) . For clinical relevance, we performed immunohistochemistry (IHC) on a PCa tissue microarray and revealed high levels of ARD1 in 62/64 (∼97%) of tumor tissues but only in 1/17 (∼6%) of normal prostate tissues had a positive staining ( Fig. 1C and Table S1 ). Taken together, these data indicate that ARD1 is up-regulated in PCa, and ARD1 may serve as a useful protein marker for prostate tumorigenesis.
Androgen Activates ARD1 in an AR-Dependent Manner in PCa. As the PCa cell lines with intact AR showed the highest levels of ARD1, we hypothesized that ARD1 might be induced by androgen. We first excluded that ARD1 was induced by androgen at the transcriptional level ( Fig. S1 A and B) . We then treated PCa cell lines with synthetic androgen (R1881) and found that ARD1 was induced at the protein level in LNCaP cells but not in AR-null PC-3 and DU-145 cells ( Fig. 2A) . However, R1881 induced ARD1 in both DU-145 and PC-3 cells when AR was ectopically expressed (Fig. 2B) . The dose-response and time-course experiments in LNCaP cells revealed that ARD1 was induced about 8 h after R1881 stimulation and gradually up-regulated as the level of AR increased (Fig. 2C) . The dose-and time-dependent induction of ARD1 by dihydrotestosterone (DHT) was also observed (Fig. S1C) . Using androgen inhibitor Casodex (CDX) or AR silencing by AR-specific siRNA in LNCaP cells, we further demonstrated that ARD1 induction by androgen was significantly decreased without AR ( Fig. 2 D and E). These results demonstrate that up-regulation of ARD1 in PCa is induced by androgen in an AR-dependent manner.
ARD1 Induces PCa Cell Proliferation, Oncogenicity, and Xenograft Tumor Growth. Next, we investigated the role of ARD1 up-regulation in prostate tumorigenesis. We compared the cell growth rates between three LNCaP clones stably expressing ARD1-specific shRNA and three stable clones expressing a control scramble shRNA. We found that the cell growth rates for the stable transfectants with ARD1 shRNA were significantly reduced compared with the stable transfectants with control shRNA (Fig. 3 A and B) . Consistently, the stable transfectants with the ARD1 shRNA formed almost none or a significantly lower number of colonies than the control stable transfectants (Fig. 3C ). Similar results were obtained when pooled stable clones were used (Fig. S2) . To assess the oncogenicity of ARD1, we performed anchorage-independent colony formation assays on soft agar. Intriguingly, the stable transfectants with the ARD1 shRNA did not generate any foci, whereas the controls generated significantly more and larger foci (Fig. 3D) . Furthermore, we implanted male SCID mice with stable transfectants expressing the ARD1 shRNA or control shRNA on the right or left hind flank of each mouse, respectively. Consistent with the in vitro data, silencing ARD1 in LNCaP cells completely suppressed xenograft tumor growth, whereas the tumor volumes increased daily for the control LNCaP cells (Fig. 3E) . Together, these data strongly suggest that ARD1 is an oncoprotein in PCa and that silencing of ARD1 reduces PCa cell proliferation and oncogenicity.
ARD1 Regulates AR-Mediated Transcription. PCa cell growth is believed to be regulated by AR-mediated transcription. We therefore examined the role of ARD1 in transcriptional regulation of AR target genes using prostate-specific antigen (PSA) and mouse mammary tumor virus (MMTV) luciferase reporter assays. As expected, the luciferase activities of both reporters were significantly induced in LNCaP cells stimulated with R1881 and in PC-3 cells following ectopic expression of AR ( Fig. S3 A and B) . Conversely, the activities of the two reporters were significantly reduced in LNCaP cells following ARD1 silencing but increased in an ARD1 dose-dependent fashion in PC-3 cells following coexpression of AR and ARD1 (Fig. S3 C and D) . Consistent with the reporter assay results, quantitative real-time (qRT-PCR) analysis of 12 known AR target genes revealed that following R1881 treatment and ARD1 silencing in LNCaP cells, the mRNA levels of the 4 AR down-regulated genes (FN1, ACPP, UGT2B13, and UGT2B17) were activated (Fig. 4A) . In contrast, the 8 AR upregulated genes including PSA, TMPRSS2, SLC45A3, FASN, ABHD2, ALDH1A3, FKBP5, and NDRG1 were down-regulated, respectively, in comparison with the mRNA levels in the control cells without silencing of ARD1 (Fig. 4A) . The mRNA level of the TMPRSS2 gene was reduced by almost 80%, whereas the transcriptional activation of the UGT2B17 gene was increased more than 10-fold (Fig. 4A) . To determine whether ARD1 acts as an AR coactivator, we performed PSA luciferase reporter assays in LNCaP cells that express AR and in PC-3 cells that lack endogenous AR expression. As expected, overexpression of ARD1 in LNCaP cells resulted in ∼3-fold activation of the PSA reporter, whereas silencing AR by AR-specific siRNA abolished the effect of ARD1 on the reporter activity (Fig. S3E) . In PC-3 cells, expression of ARD1 alone had no significant effect on the reporter (Fig. S3F) . Remarkably, coexpression of ARD1 and AR resulted in >5-fold activation of the reporter compared with the cells expressing ARD1 alone (Fig. S3F) . These results suggest that ARD1-mediated transactivation of PSA requires AR. This conclusion was further validated by qRT-PCR analysis of the transcription levels of 2 AR target genes, PSA and TMPRSS2. Consistent with the reporter data, expression of ARD1 increased PSA or TMPRSS2 transcription by >3-or >4-fold, respectively, but the inductions were completely abolished when AR was silenced by siRNA (Fig. 4B) . Furthermore, we performed ChIP analysis and showed that overexpression of ARD1 in LNCaP cells facilitated AR to interact with the PSA or TMPRSS2 promoter, compared with that in the cells without overexpression of ARD1 (Fig.  4C) . Together, these results demonstrated that ARD1-induced PCa cell growth is probably through transcriptional activation of the AR target genes, suggesting that ARD1 functions as an AR regulator.
ARD1 Acetylates AR for Target Gene Transcription. To understand the mechanism by which ARD1 promotes AR-mediated gene transcription, we examined AR level or stability following downregulation of ARD1. Intriguingly, silencing ARD1 did attenuate the PSA level but seemed to have no effect on AR level (Fig.  S4A) . Because ARD1 is an acetyltransferase, we hypothesized that ARD1 might exert its regulatory activity by acetylating AR. Reciprocal coimmunoprecipitation analyses of endogenous or exogenous proteins of ARD1 and AR in 293T and LNCaP cells demonstrated that ARD1 physically interacted with AR in vivo and in vitro (Fig. 5 A and B) . Using acetylation-specific antibody, we discovered that silencing ARD1 in LNCaP cells inhibited AR acetylation significantly (Fig. 5C ). To determine whether ARD1-mediated AR acetylation is ARD1 specific, we generated the catalytically inactive (acetyltransferase null) ARD1 mutant (ARD1 dead) as previously described (14) . Expression of the ARD1-dead mutant remarkably reduced the level of acetylated AR (Fig. 5D) . To confirm the role of ARD1 in AR acetylation, we performed an in vitro acetylation assay using purified recombinant full-length AR as the substrate, the immunoprecipitated WT-ARD1, or ARD1 dead as the enzyme, and acetylCoA as the coenzyme. We showed that ARD1 directly acetylates AR in vitro but not ARD1 dead (Fig. 5E) . Finally, we examined the possible link between AR acetylation by ARD1 and AR target gene transcription. We demonstrated that the ARD1-dead mutant was unable to induce either PSA promoter activity or PSA transactivation in LNCaP cells by luciferase reporter assay (Fig.  5F ) or by qRT-PCR (Fig. 5G) , respectively. Moreover, ARD1-dead mutant reduced the ability of AR to bind to the PSA promoters shown by ChIP analysis (Fig. 5H) . These results indicate that AR acetylation by ARD1 is required for ARD1-induced AR target gene transcription and prostate tumorigenesis.
Discussion
In this study, we reveal a unique role for ARD1 as an AR regulator in prostate tumorigenesis. We show that AR-ARD1 interaction and ARD1-dependent AR acetylation are required for transcriptional activation of AR target genes in vivo and in vitro. Silencing ARD1 in LNCaP cells results in marked inhibition of AR target gene transcription, PCa cell proliferation, and xenograft tumor growth. The significance of AR acetylation by ARD1 is further substantiated by demonstrating that silencing ARD1 or expressing an ARD1-dead mutant reduces AR acetylation and leads to reduction of AR-targeted promoter interaction and ARtarget gene expression (Fig. 5) . It has been reported that AR can be acetylated by p300 at AR lysine residues 630, 632, and 633 (KLKK) for ligand-dependent AR activation (3). Intriguingly, silencing p300 did reduce the level of total AR but did not attenuate the level of ARD1-acetylated AR (Fig. S4B) . Moreover, mutant AR in which the three lysine residues (KLKK 633 ) were replaced by glutamine still can be acetylated by ARD1 (Fig. S4C) . These data suggest that the AR acetylation site(s) for ARD1 might be different from that for p300. Further analysis will be required to identify the ARD1-specific acetylation site in AR to better understand the mechanisms by which ARD1 acetylates AR to promote AR-mediated transcription and prostate tumorigenesis.
Similar to many other AR coregulators, ARD1 is overexpressed in PCa. Although we observed the highest levels of ARD1 in PCa cell lines with AR, the levels of ARD1 in ARnegative cell lines were also relatively higher than those in the normal prostatic epithelial cell lines. It has been reported that two distinct sets of genes are activated in AR-dependent versus AR-independent PCa cells (18) . It will be interesting to determine whether the other set of genes in AR-independent PCa cells is regulated by ARD1 through a non-AR-dependent signaling pathway. Furthermore, we observed that ARD1 was upregulated in 97% (62/64) of PCa biopsies but in only 6% (1/17) of benign prostate tissues, highlighting the clinical significance of ARD1 expression in PCa. However, in our analysis of this cohort, we did not observe a correlation between the level of ARD1 and the grade of PCa. This was somehow expected that the number of grade IV tumors with strong expression of ARD1 would be reduced compared with tumors with grade II or III because some of the grade IV tumors might lose AR during the PCa progression. Future analyses of large sample sets of PCa biopsies are warranted to evaluate the potential application of ARD1 as a protein marker for PCa initiation and progression.
The data reported in this study support ARD1 as an oncoprotein in PCa, rather than as a tumor suppressor, which was recently described in breast cancer (14) . The tumor-suppressive role of ARD1 in breast cancer was shown by clinical significance of ARD1 mRNA expression, loss of heterozygosity (LOH) at the ARD1 locus, and by functional significance of ARD1 in suppression of the mammalian target of rapamycin signaling pathway (14) . In contrast, we did not detect LOH at the ARD1 locus in 12 pairs of PCa tumor specimens, nor did we detect decreased pS6K1 (T389) phosphorylation by ARD1 in LNCaP cells (Fig.  S5) . The tumor-promoting role of ARD1 was also recently described in lung cancer via acetylation and activation of β-catenin to promote cyclin D1 expression (15) . Because ARD1 is an acetyltransferase and exerts its function through its target proteins, it is very likely that the role of ARD1 in cancer is tissue specific or cell-type dependent and relies on its acetylating substrates.
In summary, our findings suggest that ARD1 is a quite unique AR regulator. It achieves its oncogenic role in prostate tumorigenesis through a positive feedback mechanism. Following ARdependent activation by androgen, ARD1 activates AR through AR-ARD1 interaction and AR acetylation. By linking the overexpression of ARD1 in PCa and ARD1-dependent acetylation of AR to AR-mediated transcription, our study provides a unique avenue for controlling AR-mediated prostate tumorigenesis by direct inhibition of ARD1 expression or AR-ARD1 interaction. Therefore, developing ARD1-specific inhibitor or AR-ARD1 interaction-disrupting peptide may be of therapeutic benefit in the treatment of PCa.
Materials and Methods
Cell Lines and Tissue Specimens. HEK293T, LNCaP, DU145, PC-3, 22Rv1, MDA PCa 2b, NCI-H660, and RWPE-2 cell lines were purchased from American Type Culture Collection (ATCC); P69, M12, M2182, and C4-2B cell lines were generously provided by Shahriar Koochekpour (Louisiana State University Health Sciences Center, New Orleans, LA); BPH-1 cell line was from Haojie Huang (Masonic Cancer Center, Minneapolis, MN). The cell lines were maintained in appropriate media according to the ATCC's protocols. The human PCa tissues were collected in the Louisiana Cancer Research Consortium with institutional review board approval. The prostate tissue microarray was purchased from US Biomax.
IHC, Immunoblotting, and Immunoprecipitation. IHC analyses of the human tissue microarray was conducted as previously described (19) using the ARD1 antibody (20) . Immunoblotting and immunoprecipitation were performed as described (21) . The antibodies used in this study are provided in SI Materials and Methods.
Plasmids and Transient or Stable Transfection of Cells. The Flag-ARD1-expressing construct was generated by inserting hARD1 cDNA into pCMVTag2b vector (Stratagene) with BamHI/HindIII restriction sites. The acetyltransferase-null ARD1 mutant (ARD1 dead) was established by substituting Ala for both Arg82 and Gly85 as previously described (22) . Luciferase reporter plasmids for PSA (PSA-Luc), MMTV (MMTV-Luc), and pcDNA3.1-His -hAR were provided by Haojie Huang. Transient transfection of plasmids or siRNAs was performed using X-tremeGENE HP DNA transfection reagent (Roche) according to the manufacturer's instructions. Lentiviral constructs expressing ARD1-specific shRNA or a control scramble shRNA were generated by inserting the reported sequences (23) into the pLKO.1 vector (Addgene) with the AgeI/EcoRI restriction sites. The lentiviral particle preparation and the LNCaP cell lines stably expressing control or ARD1 shRNA were established on the basis of the protocol previously described (19) .
Cell Proliferation and Anchorage-Independent Growth Assays. Cells were plated at a density of 2 × 10 5 cells per well in 6-cm dishes. Cells were trypsinized at days 2, 4, and 6 and counted using a hemocytometer stained with trypan blue. Clonogenic growth of cells was evaluated by assessing plating efficiency for anchorage-independent growth in soft agar at day 16 after plating, as described previously (24) .
Xenograft Tumor Growth. Stable LNCaP cells expressing shARD1 or shControl were collected in 100 μL sterile PBS and ECM gel (Sigma) mixture (50/50, vol/ vol) and inoculated subcutaneously into the right (shARD1) and left (control) flank of 5-wk-old nonobese diabetic (NOD)/SCID mice (Charles River) at 3.0 × 10 6 cells per injection site (n = 5 for each group). Mice were monitored twice a week for tumor development. Tumor size was measured weekly using a caliper. Eight weeks after inoculation, mice were killed in keeping with the policy of the humane treatment of tumor-bearing animals. All procedures follow an animal use protocol approved by the Institutional Animal Care and Use Committee of Louisiana State University Health Sciences Center New Orleans.
Luciferase Reporter Assay. Cells transfected with a combination of plasmids or siRNA, PSA-Luc, or MMTV-Luc reporter and an internal control (pRL-TK) as described in the figure legend section were harvested for luciferase activity analyses using the Dual-Luciferase Reporter Assay system (Promega) following the manufacturer's instructions.
Quantitative RT-PCR. Total RNAs were prepared with RNeasy mini kit (Qiagen) and cDNA was synthesized with SuperScript III First-Strand synthesis system (Invitrogen). Quantitative RT-PCR (qRT-PCR) was performed with SYBR Green detection method on a CFX96 Real-Time PCR Detection system (Bio-Rad). All of the primers used for qRT-PCR in this study are provided (Table S2) .
Chromatin Immunoprecipitation. ChIP assay was performed as previously described (21) with modifications. Briefly, LNCaP cells were grown in phenol red-free RPMI-1640 medium with 10% FBS (charcoal stripped) for 3 d and treated with 1 nM R1881 or vehicle for 24 h. Prepared chromatin was immunoprecipitated with anti-AR or anti-IgG antibody at 4°C overnight. The precipitated DNA was PCR amplified with primers corresponding to PSA enhancer or corresponding to the androgen-responsive elements of TMPRSS2, as previously described (25, 26) . The relative enrichment was shown using agarose gel electrophoresis.
In Vitro Acetylation Assay. The in vitro acetylation assay on AR was performed using ARD1, as described previously with modification (2, 4). Briefly, LNCaP cells grown in 100-mm culture dishes were transfected with 10 μg of pCMV-tag2b-WT-ARD1 or pCMV-tag2b-ARD1-dead expression plasmid, respectively, using X-tremeGENE HP reagent and cultured for 2 d. Cells were harvested and purified for WT ARD1 and ARD1 dead by immunoprecipitation with anti-Flag antibody (Sigma). The in vitro acetylation assay was performed in acetylation buffer [50 mM Tris-HCl (pH 8.0), 1 mM phenylmethylsulfonyl fluoride, 10% glycerol, 10 mM butyric acid, 0.2 mM EDTA, 1 mM DTT] containing 250 ng of substrate (HIS-AR; Abcam) and enzyme (the immunoprecipitated ARD1) and 1 μL acetyl-CoA (Sigma). The mixture was incubated at 30°C for 1 h. The reaction mixtures were subjected to SDS-polyacrylamide gel electrophoresis and blotted using antiacetyl-lysine primary and corresponding secondary antibodies.
Statistical Analysis. Data are expressed as mean ± SD from at least three experiments. Statistical analyses were performed by Student t test. P < 0.05 was considered statistically significant.
